Detalhe da pesquisa
1.
Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers.
Proc Natl Acad Sci U S A
; 107(5): 2177-82, 2010 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20080664
2.
A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia.
Gastroenterology
; 139(6): 1995-2004.e15, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20621683
3.
Preclinical Evaluation of 89Zr-Df-IAB22M2C PET as an Imaging Biomarker for the Development of the GUCY2C-CD3 Bispecific PF-07062119 as a T Cell Engaging Therapy.
Mol Imaging Biol
; 23(6): 941-951, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143379
4.
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Support Care Cancer
; 18(4): 423-31, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19568773
5.
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
Cancer Sci
; 100(9): 1728-34, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19575752
6.
Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Oncogene
; 38(21): 4125-4141, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30700828
7.
Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling.
Mol Cancer Ther
; 4(3): 413-25, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15767550
8.
Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.
Cancer Immunol Res
; 2(11): 1071-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25116754
9.
Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma.
Clin Lymphoma Myeloma Leuk
; 12(5): 319-24, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23040438
10.
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Leuk Lymphoma
; 53(8): 1501-8, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22239668
11.
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
J Clin Oncol
; 29(11): 1495-501, 2011 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21383291
12.
A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Clin Cancer Res
; 17(19): 6304-12, 2011 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21810918
13.
Development of vorinostat: current applications and future perspectives for cancer therapy.
Cancer Lett
; 280(2): 201-10, 2009 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-19181442
14.
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Cancer Res
; 69(7): 3060-8, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19318552
15.
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
J Clin Oncol
; 27(12): 2052-8, 2009 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19307505
16.
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Blood
; 111(3): 1060-6, 2008 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17962510